Cost-effectiveness of mirabegron compared to tolterodine ER 4 mg for overactive bladder in Canada

Yazar: Herschorn, Sender, Nazir, Jameel, Ramos, Barbara, Hakimi, Zalmai
Yayımlandı Can Urol Assoc J (2017)

Recombinant FVIIIFc Versus BAY 94-9027 for Treatment of Patients with Haemophilia A: Comparative Efficacy Using a Matching Adjusted Indirect Comparison

Yazar: Hakimi, Zalmai, Santagostino, Elena, Postma, Maarten J., Nazir, Jameel
Yayımlandı Adv Ther (2020)

Cost-effectiveness of a fixed-dose combination of solifenacin and oral controlled adsorption system formulation of tamsulosin in men with lower urinary tract symptoms associated wi...

Yazar: Nazir, Jameel, Heemstra, Lars, van Engen, Anke, Hakimi, Zalmai, Ivanescu, Cristina
Yayımlandı BMC Urol (2015)

Estimating EQ-5D and OAB-5D health state utilities for patients with overactive bladder

Yazar: Desroziers, Katia, Aballéa, Samuel, Maman, Khaled, Nazir, Jameel, Odeyemi, Isaac, Hakimi, Zalmai
Baskı/Yayın Bilgisi 2013

Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review

Yazar: Yeowell, Gillian, Smith, Philip, Nazir, Jameel, Hakimi, Zalmai, Siddiqui, Emad, Fatoye, Francis
Yayımlandı BMJ Open (2018)

Efficacy of rFIXFc versus rIX-FP for the Treatment of Patients with Hemophilia B: Matching-Adjusted Indirect Comparison of B-LONG and PROLONG-9FP Trials

Yazar: Astermark, Jan, Wojciechowski, Piotr, Aballéa, Samuel, Hakimi, Zalmai, Nazir, Jameel, Klamroth, Robert
Yayımlandı J Blood Med (2021)

Cost-effectiveness of solifenacin compared with oral antimuscarinic agents for the treatment of patients with overactive bladder in the UK

Yazar: Hakimi, Zalmai, Kelleher, Con, Aballéa, Samuel, Maman, Khaled, Nazir, Jameel, Mankowski, Colette, Odeyemi, Isaac
Yayımlandı J Mark Access Health Policy (2018)

A retrospective study of treatment persistence and adherence to α-blocker plus antimuscarinic combination therapies, in men with LUTS/BPH in the Netherlands

Yazar: Drake, Marcus J., Bowditch, Sally, Arbe, Emilio, Hakimi, Zalmai, Guelfucci, Florent, Amri, Ikbel, Nazir, Jameel
Yayımlandı BMC Urol (2017)

Economic Impact of Mirabegron Versus Antimuscarinics for the Treatment of Overactive Bladder in the UK

Yazar: Nazir, Jameel, Berling, Malin, McCrea, Charles, Fatoye, Francis, Bowditch, Sally, Hakimi, Zalmai, Wagg, Adrian
Yayımlandı Pharmacoecon Open (2017)

Content validity and test-retest reliability of patient perception of intensity of urgency scale (PPIUS) for overactive bladder

Yazar: Notte, Sherilyn M, Marshall, Thomas S, Lee, Misun, Hakimi, Zalmai, Odeyemi, Isaac, Chen, Wen-Hung, Revicki, Dennis A
Baskı/Yayın Bilgisi 2012

A retrospective study of treatment persistence and adherence to mirabegron versus antimuscarinics, for the treatment of overactive bladder in Spain

Yazar: Nazir, Jameel, Hakimi, Zalmai, Guelfucci, Florent, Khemiri, Amine, Fatoye, Francis, Blázquez, Ana María Mora, González, Marta Hernández
Yayımlandı BMC Urol (2018)

Cost Effectiveness of Mirabegron Compared with Tolterodine Extended Release for the Treatment of Adults with Overactive Bladder in the United Kingdom

Yazar: Aballéa, Samuel, Maman, Khaled, Thokagevistk, Katia, Nazir, Jameel, Odeyemi, Isaac A. O., Hakimi, Zalmai, Garnham, Andy, Toumi, Mondher
Yayımlandı Clin Drug Investig (2014)

Efficacy of rFVIIIFc versus Emicizumab for the Treatment of Patients with Hemophilia A without Inhibitors: Matching-Adjusted Indirect Comparison of A-LONG and HAVEN Trials

Yazar: Klamroth, Robert, Wojciechowski, Piotr, Aballéa, Samuel, Diamand, Françoise, Hakimi, Zalmai, Nazir, Jameel, Abad-Franch, Lydia, Lethagen, Stefan, Santagostino, Elena, Tarantino, Michael D
Yayımlandı J Blood Med (2021)